Therapeutic Solutions International Continues to Expand Chronic Traumatic Encephalopathy Intellectual Property Portfolio
January 09 2019 - 11:30AM
InvestorsHub NewsWire
Therapeutic Solutions International
Continues to Expand Chronic Traumatic
Encephalopathy Intellectual Property Portfolio
Patent filed for Autologous Neurogenic Cells in
Professional Athletes at Risk of CTE
OCEANSIDE, CA
-- January
09,
2019 -- InvestorsHub
NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced
today the addition and
expansion to their CTE portfolio of intellectual property with the
filing of a new patent application.
The invention
pertains to the field of cellular therapies, more particularly, the
invention pertains to the use of banking of autologous cells,
and the
manipulation of
autologous cells for treatment of CTE.
CTE is caused by
repetitive concussive/sub-concussive hits to the head sustained
over a period of years and is often found in football players. The
condition is characterized by memory loss, impulsive/erratic
behavior, impaired judgment, aggression, depression, and dementia.
In many patients with CTE, it is anatomically characterized by
brain atrophy, reduced mass of frontal and temporal cortices, and
medial temporal lobe.
"This new means of
obtaining autologous cells and banking them for use in the
treatment and prevention of CTE is a new and novel approach. The
autologous regenerative cells are banked for future administration
in the same patient when the patient begins to develop signs of CTE
or possesses an upregulation of markers associated with the
probability of CTE onset" said Tim G Dixon CEO
& President of Therapeutic Solutions International,
Inc.
"Banking of autologous
cells is a well-known procedure which has generated considerable
revenue despite little practical value. For example, the only FDA
approved means of utilizing cord blood cells is for treatment of
pediatric leukemias, however, in these situations, allogeneic cells
are required due to the possibility of autologous cells possessing
proclivity towards leukemic transformation. The current patent
provides tissue banking means for athletes at risk of CTE and means
of utilizing the
autologous
cells" said Dr. Thomas
Ichim, Board Member of Therapeutic Solutions International.
"The possibility of
using regenerative cells such as stem cells is limited by
a
lack of
autologous cell sources. Our
invention
provides means of banking and utilizing autologous cells for use in
patients with CTE."
About
Therapeutic Solutions International, Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's
corporate website is www.therapeuticsolutionsint.com.
These statements have
not been evaluated by the Food and Drug Administration. These
products are not intended to diagnose, treat, cure, or prevent any
disease.
Safe Harbor
Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
SEC filings. To the extent that statements in this press release
are not strictly historical, including statements as to product
launch timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
Contact
Information:
Therapeutic Solutions
International, Inc.
ir@tsoimail.com
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Apr 2023 to Apr 2024